Introduction
Every interventional clinical trial a sponsor runs comes with a parallel obligation that has nothing to do with getting a product approved: telling the public, in a defined format and on a defined timeline, that the trial happened, what it tested, and what it found. That obligation has grown steadily more detailed over the past two decades, and it has grown enough teeth — registries, lay summaries, redacted protocol disclosure, individual patient data sharing requests — that most mid-size and large sponsors now have someone whose job is specifically clinical trial disclosure and transparency. If you've seen the title on a posting and wondered whether it's a regulatory role, a clinical operations role, or a medical writing role, the honest answer is that it borrows from all three, and the mix depends on where the role sits in a given organization.
Where the Obligation Comes From
In the United States, the FDA Amendments Act of 2007 (FDAAA 801) requires sponsors of applicable clinical trials to register those trials on ClinicalTrials.gov and to post summary results within a defined window after the trial's primary completion date, regardless of whether the results are favorable. In the European Union, the Clinical Trials Regulation (536/2014) consolidated trial disclosure through the Clinical Trials Information System (CTIS), adding a requirement that sponsors publish a lay summary of trial results written for a general audience, not just a technical one. Health Canada's Public Release of Clinical Information guidance requires sponsors to proactively disclose clinical study reports and other clinical information, with personal and commercially confidential information redacted before release. Each framework has its own timelines, formats, and redaction standards, and a specialist working across multiple markets has to track all of them at once.
None of this is optional or new in concept — trial registration has been standard practice for years — but the volume and specificity of what has to be disclosed, and the speed with which regulators and the public now notice a missed deadline, has turned it into a function that needs dedicated ownership rather than something a clinical operations coordinator handles as one item on a long list.
Sponsors running trials across multiple regions often end up reconciling overlapping but not identical registry entries — a trial registered on ClinicalTrials.gov for U.S. purposes may also need a CTIS entry for EU sites, and the two records have to tell a consistent story even though they use different fields and different disclosure logic. Keeping them aligned as a protocol amends partway through a trial is one of the more tedious but consequential parts of the job, since a mismatch between registries is exactly the kind of thing an outside auditor or journalist is likely to flag.
What the Job Actually Involves
A disclosure and transparency specialist typically owns a portfolio of trials across their lifecycle from a transparency standpoint. That starts with registering a trial correctly at study start — matching the protocol, the informed consent language, and the registry entry so they tell a consistent story — and continues through updating the registry record as the protocol amends, enrollment changes, or the trial closes. Once a trial reaches its results deadline, the specialist coordinates results posting: pulling the right data elements from biostatistics, formatting them to the registry's structured fields, and making sure the submission goes in before the statutory clock runs out.
A second major piece of the work is redacted document disclosure: preparing clinical study reports, protocols, and statistical analysis plans for public release with commercially confidential information and personal data removed, following the specific redaction conventions each regulator expects. This part of the job sits closest to medical writing and regulatory publishing, since it requires reading dense clinical documents carefully enough to know what has to come out and what has to stay, and it usually involves back-and-forth with legal and medical affairs colleagues who have their own view of what counts as commercially sensitive.
A third piece, less visible but increasingly common, is handling data-sharing requests: responding to qualified researchers who request access to a trial's underlying individual patient data through channels like Vivli or a sponsor's own data-sharing portal, and coordinating the governance review that decides whether and how to grant that access. The specialist doesn't usually make the governance decision alone, but they own the process that gets a request in front of the right reviewers and tracks it to a documented outcome.
Beyond these three pillars, specialists often maintain an internal tracking system — a spreadsheet or a dedicated disclosure-management tool — that flags upcoming deadlines across an entire trial portfolio months in advance, since a single missed date can trigger public compliance notices. Building and maintaining that tracking discipline, more than any single technical skill, is often what separates a specialist a program relies on from one who is constantly reacting to deadlines that arrive as a surprise.
Who This Role Reports To and Works With
The reporting line varies more than for most regulatory titles. Some companies place disclosure and transparency inside regulatory affairs, treating it as an extension of regulatory operations. Others place it inside clinical operations, reasoning that the work tracks trial milestones more closely than regulatory submissions. A smaller number place it inside medical writing or a dedicated transparency and disclosure group that sits apart from both. Whichever reporting line a company chooses, the specialist works constantly with clinical operations (for trial status and milestones), biostatistics (for results data), legal (for redaction decisions and data-sharing governance), and medical affairs (for lay summary review and scientific accuracy). Regulatory affairs is usually a stakeholder rather than a direct manager, since the disclosure requirements are legally distinct from marketing authorization submissions even though they concern the same trials.
The Skills That Matter
Deadline discipline is the foundational skill. Disclosure obligations run on statutory clocks that don't move for a busy quarter, and a missed results-posting deadline is a matter of public record, not an internal miss that stays quiet. Beyond that, the role rewards close reading and precise writing: turning a technical statistical analysis plan into a results summary that fits a registry's structured format, or a dense clinical study report into a document a member of the public could plausibly follow in a lay summary, both take real skill and patience. Familiarity with clinical trial design and biostatistics terminology helps enormously, since the specialist has to understand enough of what a trial measured to know whether a proposed disclosure is complete and accurate, even though they aren't running the analysis themselves.
The redaction work in particular calls for judgment that's hard to fully codify: knowing the difference between information that's genuinely commercially confidential and information a sponsor would simply prefer not to disclose, and being willing to push back when legal or a program team wants to redact more than the applicable policy actually permits.
Who Moves Into This Role
People come into disclosure and transparency work from a few adjacent backgrounds. Clinical trial disclosure specialists are sometimes promoted internally from a clinical trial associate or clinical operations coordinator role, where they were already tracking trial status and registry updates as part of a broader job. Others move over from regulatory operations or regulatory publishing, bringing document formatting and submission-tracking discipline. Medical writers with an interest in the compliance side of writing, rather than the primary authoring side, are a third common source. It's less common to see someone move directly into the role without any prior clinical trials or regulatory operations exposure, since the learning curve on registry mechanics and redaction conventions is steep enough that most companies want at least some adjacent experience.
Why This Role Is Growing
Three trends are pushing more sponsors to formalize this function rather than treat it as a side task. First, enforcement and public scrutiny of registration and results-posting compliance have increased; academic groups and journalists periodically publish audits of registry compliance by sponsor, and being named in one of those audits is reputationally costly. Second, the EU Clinical Trials Regulation's lay summary requirement created an entirely new deliverable that didn't exist under the prior directive, and writing genuinely accessible lay summaries at scale is harder than it sounds. Third, data-sharing expectations from journals, funders, and some regulators have normalized researcher access requests as a routine occurrence rather than a rare exception, which means someone has to own that intake and governance process on an ongoing basis. Together, these trends mean the role has moved from something a generalist absorbed into a defined, resourced function at most mid-size and large sponsors.
How to Position Yourself for This Kind of Role
If you're in clinical operations, regulatory publishing, or medical writing and want to move toward disclosure and transparency work, the most useful preparation is hands-on registry experience: volunteer to own a ClinicalTrials.gov or CTIS record update, sit in on a redaction review, or ask to shadow a data-sharing request through its governance process. In an interview, be ready to talk concretely about registry structure and disclosure timelines rather than only regulatory affairs in the abstract — hiring managers for this role are looking for someone who already understands that a results-posting deadline is a hard date, not a target.
Conclusion
Clinical trial disclosure and transparency work sits at an unusual intersection of regulatory compliance, clinical operations, and public communication, and it rewards people who like precise, deadline-driven documentation work with a genuine public-interest dimension. It's rarely anyone's first regulatory job, but for someone with a few years of clinical operations, publishing, or medical writing experience looking for a role with clear ownership and visible impact, it's worth a closer look the next time it shows up on a posting.